← Back to Analyst Consensus 
KRYS Buy
Krystal Biotech, Inc.
Current Price —
Implied Upside —
Analysts 20
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 2, 2026 (7 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $361 | 44% |
| Sep 21, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| Aug 14, 2026 | RBC Capital | initiate | — → Outperform | — | 55% |
| Aug 4, 2026 | Citigroup | maintain | Buy → Buy | $386 | 54% |
| Jul 14, 2026 | B of A Securities | maintain | Buy → Buy | $396 | 53% |
| Jun 18, 2026 | TD Cowen | maintain | Buy → Buy | $403 | 54% |
| Jun 16, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $361 | 44% |
| Jun 1, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $310 | 44% |
| May 22, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $310 | 44% |
| May 18, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $310 | 44% |
| May 5, 2026 | Citigroup | maintain | Buy → Buy | $378 | 54% |
| May 5, 2026 | Evercore ISI Group | maintain | Outperform → Outperform | $300 | 58% |
| May 4, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $310 | 44% |
| Mar 27, 2026 | Wolfe Research | initiate | — → Peer Perform | — | 54% |
| Feb 25, 2026 | Guggenheim | maintain | Buy → Buy | $284 | 52% |
| Feb 18, 2026 | Citigroup | maintain | Buy → Buy | $371 | 54% |
| Feb 18, 2026 | Chardan Capital | maintain | Buy → Buy | $323 | 47% |
| Feb 17, 2026 | Jefferies | maintain | Buy → Buy | $371 | 52% |
| Feb 2, 2026 | Goldman Sachs | maintain | Buy → Buy | $327 | 54% |
| Jan 22, 2026 | B of A Securities | maintain | Buy → Buy | $318 | 53% |
| Jan 12, 2026 | Citigroup | maintain | Buy → Buy | $336 | 54% |
| Jan 9, 2026 | TD Cowen | maintain | Buy → Buy | $306 | 54% |
| Jan 9, 2026 | Citigroup | maintain | Buy → Buy | $320 | 54% |
| Jan 9, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $310 | 44% |
| Jan 6, 2026 | Citigroup | upgrade | Neutral → Buy | $309 | 54% |
| Nov 4, 2025 | Citigroup | maintain | Neutral → Neutral | $198 | 54% |
| Nov 4, 2025 | Chardan Capital | maintain | Buy → Buy | $220 | 47% |
| Oct 17, 2025 | B of A Securities | maintain | Buy → Buy | $255 | 53% |
| Sep 15, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $240 | 44% |
| Aug 22, 2025 | Chardan Capital | maintain | Buy → Buy | $216 | 47% |
| Aug 22, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $240 | 44% |
| Aug 5, 2025 | Citigroup | maintain | Neutral → Neutral | $166 | 54% |
| Aug 5, 2025 | Chardan Capital | maintain | Buy → Buy | $219 | 47% |
| Jul 25, 2025 | Chardan Capital | maintain | Buy → Buy | $219 | 47% |
| Jul 25, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $240 | 44% |
| Jul 22, 2025 | B of A Securities | maintain | Buy → Buy | $192 | 53% |
| Jul 10, 2025 | Citigroup | maintain | Neutral → Neutral | $176 | 54% |
| Jul 1, 2025 | Clear Street | initiate | — → Buy | $190 | 48% |
| Jun 24, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $240 | 44% |
| May 16, 2025 | Citigroup | maintain | Neutral → Neutral | $155 | 54% |
| May 7, 2025 | Guggenheim | maintain | Buy → Buy | $189 | 52% |
| May 7, 2025 | Chardan Capital | maintain | Buy → Buy | $219 | 47% |
| May 6, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $240 | 44% |
| Apr 29, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $240 | 44% |
| Apr 28, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $240 | 44% |
| Mar 5, 2025 | Jefferies | initiate | — → Buy | $245 | 52% |
| Feb 28, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $221 | 44% |
| Feb 20, 2025 | Citigroup | maintain | Neutral → Neutral | $215 | 54% |
| Feb 20, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $215 | 50% |
| Feb 20, 2025 | Chardan Capital | maintain | Buy → Buy | $218 | 47% |
Price Target Trend
Jul 5, 2026 Oct 26, 2026
EPS Estimates
0y —
+1y —
0q —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days